After 17 years of research, India’s homegrown dengue vaccine reaches final trials

India's first indigenous dengue vaccine, DengiAll, developed by Panacea Biotec with ICMR support, has completed or nearly completed Phase-III trials involving over 10,000 volunteers. DengiAll is designed to protect against all four dengue virus serotypes in a single shot, showing 77–82% efficacy in earlier trials. If interim Phase-III results are positive, Panacea Biotec may seek regulatory approval soon, potentially transforming dengue prevention in India and other tropical regions.